10x Genomics
TXG
76.10
-4.56
-5.65%
10x Genomics
US · TXG
#1311 by market cap
Listed 2019
76.10
-4.56
-5.65%
Live - 5344 symbols - heartbeat 16s ago
· 2026-10-08 06:39
Pre-market
73.50
-3.42%
After-hours
76.20
+0.13%
Overnight
75.78
-0.42%
- Market cap
- 9.92B
- P/E (TTM)i
- -128.98
- P/Bi
- 12.01
- EPSi
- -0.35
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on TXG?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 11 analysts
Buy
Avg price target
64.67 -15.0%
Price target rangecurrent 76.10
Low47.00
Avg64.67
High110.00
Buy 55%
Hold 45%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-29 | William Blair | -- | BUY | -- |
| 2026-09-29 | Leerink Partners | -- | HOLD | 90.00 |
| 2026-09-25 | Argus Research | -- | BUY | 110.00 |
| 2026-09-01 | RBC Capital | -- | HOLD | 70.00 |
| 2026-08-10 | CCORF | -- | BUY | 60.00 |
| 2026-08-07 | William Blair | -- | BUY | -- |
| 2026-08-07 | BofA Securities | -- | HOLD | -- |
| 2026-08-07 | Jefferies | -- | BUY | 53.00 |
| 2026-08-07 | Stifel | -- | BUY | 50.00 |
| 2026-08-07 | Citi | -- | HOLD | 50.00 |
| 2026-08-06 | CCORF | -- | BUY | 50.00 |
| 2026-08-06 | Barclays | -- | BUY | 52.00 |
| 2026-07-15 | TD Cowen | -- | HOLD | 47.00 |
| 2026-07-13 | CCORF | -- | BUY | 50.00 |
| 2026-07-01 | Piper Sandler | -- | HOLD | 42.00 |
| 2026-06-24 | Barclays | -- | BUY | 40.00 |
| 2026-06-10 | CCORF | -- | BUY | 32.00 |
| 2026-05-14 | BofA Securities | -- | HOLD | -- |
| 2026-05-12 | Morgan Stanley | -- | HOLD | 22.00 |
| 2026-05-08 | CCORF | -- | BUY | 32.00 |
| 2026-05-08 | William Blair | -- | BUY | -- |
| 2026-05-08 | Deutsche Bank | -- | HOLD | 23.00 |
| 2026-05-08 | Barclays | -- | BUY | 30.00 |
| 2026-05-07 | TD Cowen | -- | HOLD | 25.00 |
| 2026-05-07 | BofA Securities | -- | HOLD | 30.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Strong Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1 1
■ Upgrades■ Downgrades
- 1 upgrade vs 1 downgrade among tracked analyst rating changes.
- Most recent: William Blair moved from Hold to Buy on 2026-04-20.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-04-20 | William Blair | HOLD → BUY | -- |
| 2025-12-11 | Citi | BUY → HOLD | 18.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-06 | After close | ±13.67% | +14.10% (beat) |
| 2026/Q1 | 2026-05-07 | After close | ±13.21% | -3.66% (in line) |
| 2025/Q4 | 2026-02-12 | After close | ±16.03% | +3.48% (in line) |
| 2025/Q3 | 2025-11-06 | After close | ±21.63% | +17.31% (in line) |
| 2025/Q2 | 2025-08-07 | After close | ±20.99% | -3.98% (in line) |
| 2025/Q1 | 2025-05-08 | After close | ±30.30% | +1.62% (in line) |
| 2024/Q4 | 2025-02-12 | After close | ±18.78% | -0.50% (in line) |
| 2024/Q3 | 2024-10-29 | After close | ±20.34% | +4.43% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±15.88% | +4.50% (in line) |
| 2024/Q1 | 2024-04-30 | After close | ±17.27% | -8.06% (in line) |
| 2023/Q4 | 2024-02-15 | After close | ±17.07% | +0.79% (in line) |
| 2023/Q3 | 2023-11-02 | After close | ±15.08% | +8.73% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 06:39:55 · For reference only, not investment advice and not tailored to your situation.